Annuncio • May 16
Krka, d. d., Annual General Meeting, Jul 09, 2026 Krka, d. d., Annual General Meeting, Jul 09, 2026, at 13:00 Central European Standard Time. Reported Earnings • May 15
First quarter 2026 earnings released: EPS: €3.69 (vs €4.97 in 1Q 2025) First quarter 2026 results: EPS: €3.69 (down from €4.97 in 1Q 2025). Revenue: €565.8m (up 8.4% from 1Q 2025). Net income: €120.9m (down 21% from 1Q 2025). Profit margin: 21% (down from 29% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • Apr 05
Dividend of €9.10 announced Shareholders will receive a dividend of €9.10. Ex-date: 21st July 2026 Payment date: 23rd July 2026 Dividend yield will be 0.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (63% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 12
Full year 2025 earnings released: EPS: €13.21 (vs €11.60 in FY 2024) Full year 2025 results: EPS: €13.21 (up from €11.60 in FY 2024). Revenue: €2.04b (up 6.9% from FY 2024). Net income: €403.2m (up 13% from FY 2024). Profit margin: 20% (up from 19% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Jul 15
Upcoming dividend of €8.25 per share Eligible shareholders must have bought the stock before 22 July 2025. Payment date: 24 July 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Polish dividend payers (7.2%). Higher than average of industry peers (2.8%). Buy Or Sell Opportunity • Jul 09
Now 20% undervalued Over the last 90 days, the stock has risen 15% to zł834. The fair value is estimated to be zł1,048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has grown by 3.0%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings are also forecast to grow by 2.7% per annum over the same time period. Declared Dividend • May 18
Dividend of €8.25 announced Shareholders will receive a dividend of €8.25. Ex-date: 22nd July 2025 Payment date: 24th July 2025 Dividend yield will be 1.1%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (70% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 10% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annuncio • May 16
Krka, d. d., Annual General Meeting, Jul 10, 2025 Krka, d. d., Annual General Meeting, Jul 10, 2025. Reported Earnings • May 15
First quarter 2025 earnings released: EPS: €4.97 (vs €3.21 in 1Q 2024) First quarter 2025 results: EPS: €4.97 (up from €3.21 in 1Q 2024). Revenue: €522.1m (up 7.4% from 1Q 2024). Net income: €152.2m (up 54% from 1Q 2024). Profit margin: 29% (up from 20% in 1Q 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 13
Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023) Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Post-clinical trial products Approved (during full year): 18 Launched (during full year): 10 Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 13
Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023) Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 15
Third quarter 2024 earnings released: EPS: €1.93 (vs €2.11 in 3Q 2023) Third quarter 2024 results: EPS: €1.93 (down from €2.11 in 3Q 2023). Revenue: €449.2m (up 6.9% from 3Q 2023). Net income: €59.2m (down 9.3% from 3Q 2023). Profit margin: 13% (down from 16% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year. Buy Or Sell Opportunity • Jul 25
Now 20% undervalued Over the last 90 days, the stock has risen 9.9% to zł600. The fair value is estimated to be zł751, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings are also forecast to grow by 4.6% per annum over the same time period. Reported Earnings • Jul 19
Second quarter 2024 earnings released: EPS: €3.99 (vs €2.62 in 2Q 2023) Second quarter 2024 results: EPS: €3.99 (up from €2.62 in 2Q 2023). Revenue: €499.3m (up 8.0% from 2Q 2023). Net income: €123.0m (up 52% from 2Q 2023). Profit margin: 25% (up from 18% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Jul 16
Upcoming dividend of €7.50 per share Eligible shareholders must have bought the stock before 23 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 72% but the company is paying out more than the cash it is generating. Trailing yield: 5.1%. Lower than top quartile of Polish dividend payers (7.3%). Higher than average of industry peers (2.2%). Buy Or Sell Opportunity • Jun 05
Now 21% undervalued Over the last 90 days, the stock has risen 4.5% to zł560. The fair value is estimated to be zł707, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 7.0% per annum over the same time period. Declared Dividend • May 19
Dividend of €7.50 announced Shareholders will receive a dividend of €7.50. Ex-date: 23rd July 2024 Payment date: 25th July 2024 Dividend yield will be 1.4%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (69% earnings payout ratio) but not covered by cash flows (166% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 17
First quarter 2024 earnings released: EPS: €3.21 (vs €2.87 in 1Q 2023) First quarter 2024 results: EPS: €3.21 (up from €2.87 in 1Q 2023). Revenue: €486.1m (up 6.1% from 1Q 2023). Net income: €98.9m (up 11% from 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 4% per year. Reported Earnings • Apr 14
Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022) Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Approved (during full year): 10 Launched (during full year): 8 Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year. Reported Earnings • Mar 14
Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022) Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year. Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: €2.11 (vs €2.10 in 3Q 2022) Third quarter 2023 results: EPS: €2.11 (up from €2.10 in 3Q 2022). Revenue: €420.1m (up 9.2% from 3Q 2022). Net income: €65.3m (flat on 3Q 2022). Profit margin: 16% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 7% per year. Reported Earnings • Jul 20
Second quarter 2023 earnings released: EPS: €2.62 (vs €4.67 in 2Q 2022) Second quarter 2023 results: EPS: €2.62 (down from €4.67 in 2Q 2022). Revenue: €462.2m (up 8.8% from 2Q 2022). Net income: €80.9m (down 44% from 2Q 2022). Profit margin: 18% (down from 34% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 12% per year. Buying Opportunity • Jul 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 5.3%. The fair value is estimated to be zł637, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings is also forecast to grow by 2.6% per annum over the same time period. Upcoming Dividend • Jul 11
Upcoming dividend of €6.60 per share at 5.7% yield Eligible shareholders must have bought the stock before 18 July 2023. Payment date: 20 July 2023. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (7.1%). Higher than average of industry peers (2.7%). Buying Opportunity • May 24
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be zł633, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings is also forecast to grow by 4.6% per annum over the same time period. Reported Earnings • May 18
First quarter 2023 earnings released: EPS: €2.87 (vs €2.91 in 1Q 2022) First quarter 2023 results: EPS: €2.87 (down from €2.91 in 1Q 2022). Revenue: €458.2m (up 5.9% from 1Q 2022). Net income: €89.0m (down 1.5% from 1Q 2022). Profit margin: 19% (down from 21% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year. Reported Earnings • Mar 17
Full year 2022 earnings released: EPS: €11.69 (vs €9.92 in FY 2021) Full year 2022 results: EPS: €11.69 (up from €9.92 in FY 2021). Revenue: €1.72b (up 9.7% from FY 2021). Net income: €363.3m (up 18% from FY 2021). Profit margin: 21% (up from 20% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Jan 31
Krka Reportedly Eyes Promoter Stake in Unichem Laboratories Krka, d. d. (LJSE:KRKG) is in discussions to acquire the promoter’s stake in Mumbai-based Unichem Laboratories Limited (BSE:506690), said two people aware of the development. Promoter Prakash Amrut Mody & family owns a 50.93% stake in the listed entity. An acquisition of this stake will trigger an open offer for an additional 26% of equity. Reported Earnings • Nov 18
Third quarter 2022 earnings released: EPS: €2.10 (vs €2.02 in 3Q 2021) Third quarter 2022 results: EPS: €2.10 (up from €2.02 in 3Q 2021). Revenue: €384.8m (up 4.6% from 3Q 2021). Net income: €65.3m (up 4.1% from 3Q 2021). Profit margin: 17% (in line with 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 12% per year. Reported Earnings • Jul 22
Second quarter 2022 earnings released: EPS: €4.67 (vs €2.93 in 2Q 2021) Second quarter 2022 results: EPS: €4.67 (up from €2.93 in 2Q 2021). Revenue: €425.0m (up 3.0% from 2Q 2021). Net income: €145.3m (up 59% from 2Q 2021). Profit margin: 34% (up from 22% in 2Q 2021). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to stay flat compared to a 7.2% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year. Upcoming Dividend • Jul 12
Upcoming dividend of €5.63 per share Eligible shareholders must have bought the stock before 19 July 2022. Payment date: 21 July 2022. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (8.4%). Higher than average of industry peers (2.6%). Reported Earnings • May 20
First quarter 2022 earnings released: EPS: €2.91 (vs €2.77 in 1Q 2021) First quarter 2022 results: EPS: €2.91 (up from €2.77 in 1Q 2021). Revenue: €432.5m (up 9.3% from 1Q 2021). Net income: €90.4m (up 4.5% from 1Q 2021). Profit margin: 21% (down from 22% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 5.5% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 17% per year. Reported Earnings • Mar 19
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: €9.92 (up from €9.27 in FY 2020). Revenue: €1.57b (up 2.0% from FY 2020). Net income: €309.2m (up 6.3% from FY 2020). Profit margin: 20% (in line with FY 2020). Post-clinical trial products Approved (during full year): 14 Revenue exceeded analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 2.5%, compared to a 7.4% growth forecast for the pharmaceuticals industry in Poland. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year. Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment deteriorated over the past week After last week's 15% share price decline to zł430, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 95% over the past three years. Reported Earnings • Nov 19
Third quarter 2021 earnings released: EPS €2.02 (vs €1.61 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €368.0m (up 3.2% from 3Q 2020). Net income: €62.7m (up 25% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 30
Second quarter 2021 earnings released: EPS €2.93 (vs €2.40 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €412.8m (up 21% from 2Q 2020). Net income: €91.5m (up 21% from 2Q 2020). Profit margin: 22% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 25% per year. Upcoming Dividend • Jul 13
Upcoming dividend of €5.00 per share Eligible shareholders must have bought the stock before 20 July 2021. Payment date: 22 July 2021. Trailing yield: 4.7%. Lower than top quartile of Polish dividend payers (5.8%). Higher than average of industry peers (2.7%). Reported Earnings • May 22
First quarter 2021 earnings released: EPS €2.77 (vs €2.72 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €395.8m (down 14% from 1Q 2020). Net income: €86.5m (up 1.0% from 1Q 2020). Profit margin: 22% (up from 19% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year. Reported Earnings • Apr 17
Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Post-clinical trial products Approved (during full year): 20 Launched (during full year): 29 Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year. Reported Earnings • Mar 19
Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 22% per year. Is New 90 Day High Low • Dec 23
New 90-day high: zł420 The company is up 9.0% from its price of zł385 on 24 September 2020. The Polish market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł475 per share. Is New 90 Day High Low • Dec 03
New 90-day high: zł399 The company is up 4.0% from its price of zł383 on 04 September 2020. The Polish market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł390 per share. Reported Earnings • Nov 20
Third quarter 2020 earnings released: EPS €1.61 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €356.4m (up 8.2% from 3Q 2019). Net income: €50.4m (up 55% from 3Q 2019). Profit margin: 14% (up from 9.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.